Glen Eagle Advisors, LLC Neurocrine Biosciences Inc Transaction History

Glen Eagle Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Aug 13, 2024	BUY	$96.16 - $135.15 $10,577 - $14,866	110 New	110 $10.6 Million
Q1 2020 Aug 13, 2024	SELL	$75.11 - $113.76 $4,882 - $7,394	-65 Closed	0 $0
Q4 2019 Aug 13, 2024	BUY	$86.8 - $118.57 $5,642 - $7,707	65 New	65 $6.99 Million
Q1 2018 Aug 13, 2024	SELL	$75.88 - $92.43 $4,173 - $5,083	-55 Closed	0 $0
Q3 2017 Aug 13, 2024	BUY	$47.97 - $61.28 $2,638 - $3,370	55 New	55 $3.37 Million
Q2 2017 Aug 12, 2024	BUY	N/A	55	55 $2.53 Million

654

96.5M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.4B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.